NUTRIPHYT
ActiveSummary
The computed 12-month bankruptcy probability of NUTRIPHYT is 3.2% (moderate). The annual accounts of NUTRIPHYT for financial year 2025 show a net loss of 70% of the equity at the start of that year. The 2025 annual accounts show equity of €453,740 and a net result of -€1.1m. Equity is growing by about 10% per year across the filed financial years. Its solvency ranks better than 12% of 6,153 sector peers (NACE 46, financial year 2025). The company has been active since 2002 and the Belgian Official Gazette contains no insolvency or warning signals.
Directors
Board 5
Day-to-day management 1
Permanent representatives 4
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| ERUDITE |
|
| Erudite.Health |
|
| InflamXfrom an act |
|
| SMARD |
|
| BV Lucalot |
|
| Hadewijch Devriendt |
|
| Pure Lynn |
|
| Medeca |
|
| Dapacem B.V. |
|
| Keizerswaal B.V. |
|
| Lagomonte B.V. |
|
| PURES |
|
| VERGAUWE CONSULTANCY |
|
Owners and capital
Owners
2 ownersChain of control
- Erudite.Health
- NUTRIPHYT
Highest known parent: Erudite.Health. The sources do not say who stands above it.
Owners 2
- Erudite.Healthparent100%
-
11.67%
According to the 2025 annual accounts of NUTRIPHYT and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- 14-11-2023 Capital stated in the deed · €196,500 · 120 shares